SELDI protein profiling of dunning R-3327 derived cell lines: Identification of molecular markers of prostate cancer progression

Prostate

Volumn 67, Issue 14, 2007, Pages 1565-1575

  Malik, Gunjan ^a,d   Rojahn, Elizabeth ^b   Ward, Michael D ^a   Gretzer, Mathew B ^c   Partin, Alan W ^b   Semmes, O John ^a   Veltri, Robert W ^b,e  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d San Antonio Cancer Institute   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Dunning rat tumor cell lines; Histone 2B; Metastasis; Prostate cancer; Proteomics; SELDI TOF

Indexed keywords

HISTONE H2B; MOLECULAR MARKER;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FRACTIONATION; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; RAT; SEQUENCE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RATS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 35148841921     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20646     Document Type: Article

References (72)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics. CA Cancer J Clin 2005;55(1):10-30.
2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101(10 Suppl):2371-2490.
3. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361):955-964.
4. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
5. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283-1290.
6. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274(15):1214-1220.
7. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - What we have learned and where we are going. J Urol 1999;162(2):293-306.
8. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170(3):723-726.
9. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology 2001;57(6):1105-1111.
10. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999;35(5-6):459-463.
11. Russell PJ, Voeks DJ. Animal models of prostate cancer. Methods Mol Med 2003;81:89-112.
12. Nora MN, Christopher JL, von Eschenbach AC, Patricia T. Model systems of prostate cancer: Uses and limitations. Cancer Metastasis Rev 1998;17(4):361-371.
13. Isaacs JT, Heston WD, Weissman RM, Coffey DS. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 1978;38(11 Pt 2):4353-4359.
14. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9(3):261-281.
15. Dunning WF. Prostate cancer in the rat. Natl Cancer Inst Monogr 1963;12:351-369.
16. Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW. The Dunning model. Prostate 2000;43(4):295-302.
17. Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, Veltri RW. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Prostate 2004;60(4):325-331.
18. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11(3):1073-1085.
19. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51(1):102-112.
20. Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam BL, Wright GL Jr, Semmes OJ. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130(1):98-104.
21. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006;5(10):1957-1967.
22. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr, Semmes OJ. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004;10(5):1625-1632.
23. Semmes OJ, Malik G, Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J Cell Biochem 2006;98(3):496-503.
24. Conrads TP, Hood BL, Issaq HJ, Veenstra TD. Proteomic patterns as a diagnostic tool for early-stage cancer: A review of its progress to a clinically relevant tool. Mol Diagn 2004;8(2):77-85.
25. Fung ET, Enderwick C. ProteinChip clinical proteomics: Computational challenges and solutions. BioTechniques 2002;32(Computational Proteomics Suppl.):S34-S41.
26. Grizzle WE, Semmes OJ, Basier J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genito-urinary oncology. Urol Oncol 2004;22(4):337-343.
27. Henderson NA, Steele RJ. SELDI-TOF proteomic analysis and cancer detection. Surgeon 2005;3(6):383-390, 422.
28. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006;5(10):1760-1771.
29. Wright GL Jr. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2(6):549-563.
30. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47(4):456-462.
31. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65(1):323-332.
32. Wright GLJ, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. Proteinchip(R) surface enhanced laser desorption/ ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2(5/6):264-276.
33. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48(10):1835-1843.
34. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005;41(3):634-642.
35. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50(1):54-63.
36. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: Proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004;211(2):227-234.
37. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF III. New approaches to proteomic analysis of breast cancer. Proteomics 2001;1(10):1205-1215.
38. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol 2001;12(1):65-69.
39. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003;309(1):18-25.
40. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002;19(4):319-326.
41. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem Pharmacol 2006;72(11):1563-1569.
42. Chakravarthy S, Park YJ, Chodaparambil J, Edayathumangalam RS, Luger K. Structure and dynamic properties of nucleosome core particles. FEBS Lett 2005;579(4):895-898.
43. Fernandez-Capetillo O, Allis CD, Nussenzweig A. Phosphorylation of histone H2B at DNA double-strand breaks. J Exp Med 2004;199(12):1671-1677.
44. Kamakaka RT, Biggins S. Histone variants: Deviants? Genes Dev 2005;19(3):295-310.
45. Yoon HG, Choi Y, Cole PA, Wong J. Reading and function of a histone code involved in targeting corepressor complexes for repression. Mol Cell Biol 2005;25(1):324-335.
46. Brower-Toland B, Wacker DA, Fulbright RM, Lis JT, Kraus WL, Wang MD. Specific contributions of histone tails and their acetylation to the mechanical stability of nucleosomes. J Mol Biol 2005;346(1):135-146.
47. Ito T, Ikehara T, Nakagawa T, Kraus WL, Muramatsu M. p300-mediated acetylation facilitates the transfer of histone H2A-H2B dimers from nucleosomes to a histone chaperone. Genes Dev 2000;14(15):1899-1907.
48. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-3473.
49. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63(22):7638-7640.
50. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65(3):708-712.
51. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65(13):5965-5973.
52. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262-1266.
53. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54(10):2577-2581.
54. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. LNCaP progression model of human prostate cancer: Androgen- independence and osseous metastasis. Prostate 2000;44(2):91-103 Jul 101;144(102).
55. Fearon ER. A genetic basis for the multi-step pathway of colorectal tumorigenesis. Princess Takamatsu Symp 1991;22:37-48.
56. Fearon ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 1994;39:123-147.
57. Knudson AG. Two genetic hits (more or less) to cancer. Nature Rev 2001;1(2):157-162.
58. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001;20(24):3156-3165.
59. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9(4):138-141.
60. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002;21(35):5400-5413.
61. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293(5532):1068-1070.
62. Robertson KD. DNA methylation and chromatin - Unraveling the tangled web. Oncogene 2002;21(35)5361-5379.
63. Berger SL, Felsenfeld G. Chromatin goes global. Mol Cell 2001;8(2):263-268.
64. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nature Rev 2002;2(12):918-926.
65. Duensing S, Duensing A, Flores ER, Do A, Lambert PF, Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 2001;75(16):7712-7716.
66. Holth LT, Chadee DN, Spencer VA, Samuel SK, Safneck JR, Davie JR. Chromatin, nuclear matrix and the cytoskeleton: Role of cell structure in neoplastic transformation (review). Int J Oncol 1998;13(4):827-837.
67. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-1080.
68. Konety BR, Getzenberg RH. Nuclear structural proteins as biomarkers of cancer. J Cell Biochem 1999;75(Suppl. S32):183-191.
69. Leman ES, Getzenberg RH. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002;86(2):213-223.
70. Reeves R, Beckerbauer L. HMGI/Y proteins: Flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519(1-2):13- 29.
71. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB. Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer. Cancer Res 2000;60(8):2067-2076.
72. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991;51(24):6514-6520.